Stockscreener 앱 받기
55.46
6.38%
-3.78
전일 마감가:
$59.24
열려 있는:
$59.05
하루 거래량:
181.19K
Relative Volume:
0.69
시가총액:
$370.62M
수익:
-
순이익/손실:
$-19.44M
주가수익비율:
-16.13
EPS:
-3.4389
순현금흐름:
$-10.83M
1주 성능:
-3.97%
1개월 성능:
-17.27%
6개월 성능:
+65.50%
1년 성능:
+24.13%
1일 변동 폭
$55.14
$60.85
1주일 범위
$54.90
$61.30
52주 변동 폭
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
55.46 | 395.88M | 0 | -19.44M | -10.83M | -3.4389 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 개시 | Morgan Stanley | Overweight |
| 2025-11-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 개시 | Leerink Partners | Outperform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Market Catalysts: Will Monopar Therapeutics Inc benefit from sector rotationWeekly Stock Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Should I add Monopar Therapeutics Inc. stock to my portfolio2025 Retail Activity & AI Based Trade Execution Alerts - mfd.ru
Stocks showing improved relative strength: Monopar Therapeutics - MSN
The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research - Defense World
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease - TipRanks
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Bull Bear: Why is Monopar Therapeutics Inc stock going down2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily
Breakout Move: Will Monopar Therapeutics Inc outperform tech stocksStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Leaders: Will Monopar Therapeutics Inc outperform tech stocksMarket Rally & Growth Focused Entry Reports - baoquankhu1.vn
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
Monopar Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Monopar Therapeutics: Tiny Cancer-Drug Stock Caught Between Speculation And Survival - AD HOC NEWS
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December - MarketBeat
Fundamentals Check: Why is Monopar Therapeutics Inc stock going downJuly 2025 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Technical Reactions to MNPR Trends in Macro Strategies - Stock Traders Daily
Price Action: Is Monopar Therapeutics Inc impacted by rising rates2025 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
History Review: Is CO2 Energy Transition Corp a stock for growth or value investors2025 Geopolitical Influence & High Win Rate Trade Tips - baoquankhu1.vn
BTIG Reiterates Buy Rating for MNPR with $104 Target Price | MNP - GuruFocus
Monopar Therapeutics' (MNPR) "Buy" Rating Reiterated at BTIG Research - MarketBeat
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts - TipRanks
BTIG reiterates Buy rating on Monopar Therapeutics stock ahead of NDA submission - Investing.com Canada
Momentum Shift: How strong is Monopar Therapeutics Inc stock balance sheetMarket Volume Summary & Technical Entry and Exit Alerts - Bộ Nội Vụ
Aug Closing: Is Monopar Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Earnings Recap & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Sentiment Recap: Is Monopar Therapeutics Inc. stock a safe haven assetInflation Watch & Reliable Intraday Trade Alerts - Bộ Nội Vụ
CEO Moves: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivals2025 Institutional Moves & Daily Market Momentum Tracking - Bộ Nội Vụ
How dovish Fed policy supports Monopar Therapeutics Inc. (1IY0) stock2025 Market WrapUp & Weekly Watchlist for Hot Stocks - Улправда
Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Monopar Therapeutics initiated with an Overweight at Morgan Stanley - TipRanks
Morgan Stanley Initiates Coverage on Monopar Therapeutics (MNPR) - GuruFocus
Morgan Stanley initiates Monopar Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Buy” from Brokerages - Defense World
Why Monopar Therapeutics Inc. stock appeals to analystsPrice Action & Daily Growth Stock Tips - ulpravda.ru
Can Monopar Therapeutics Inc. stock maintain operating marginsTrade Exit Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
How risky is Monopar Therapeutics Inc. stock nowWeekly Investment Recap & Free Community Consensus Stock Picks - Улправда
symbol__ Stock Quote Price and Forecast - CNN
Will Monopar Therapeutics Inc. stock return to pre crisis levelsJuly 2025 News Drivers & Fast Moving Stock Watchlists - Улправда
Can Monopar Therapeutics Inc. stock hit record highs again2025 Macro Impact & Weekly Return Optimization Alerts - Улправда
Published on: 2026-01-09 02:26:30 - ulpravda.ru
Published on: 2026-01-09 02:04:15 - Улправда
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):